Skip to main content
Clinical Trials/ACTRN12612001027808
ACTRN12612001027808
Not yet recruiting
Phase 3

Investigation into the Acute and Chronic Effects of Longvida Curcumin on Cognitive Function, Mood and Biomarkers of Health in a Cognitively Healthy Elderly Population Compared to an Elderly Population with Cognitive Decline

Swinburne University of Technology, Centre for Human Psychopharmacology0 sites60 target enrollmentSeptember 24, 2012

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Cognitive function
Sponsor
Swinburne University of Technology, Centre for Human Psychopharmacology
Enrollment
60
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 24, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Swinburne University of Technology, Centre for Human Psychopharmacology

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female.
  • 2\. Aged 65\-80 years.
  • 3\. Willing and able to provide written informed consent.
  • 4\. Understands and is willing and able to comply with all study procedures.
  • 5\. Free from history of stroke, other neurological conditions (e.g. Parkinsons, epilepsy), depression, psychiatric disorders, low base line intellect, alcohol abuse past / present.
  • 6\. Cognitively healthy participants must be free from any form of cognitive impairment. For the cognitively declined particpants, participants must have objective memory impairment for age and education level.
  • 7\. Free from dementia.
  • 8\. English speaking.
  • 9\. Must have normal or corrected vision.
  • 10\. Free from other medical conditions which may affect ability to participate in the study

Exclusion Criteria

  • 1\. Any significant concurrent illness including any auto\-immune disorder, bleeding disorders, heart conditions, diabetes, glaucoma, high blood pressure or osteoporosis.
  • 2\. Any known or suspected food allergies
  • 3\. Smokers and users of recreational drugs (except alcohol and other food grade actives).
  • 4\. Have participated in any other study involving an investigational product in the last 4 weeks.
  • 5\. Taking any of the following: anti\-coagulant drugs (Warfarin,Heparin, Plavix); anti\-cholinergics or acetylcholinesterase inhibitors: bethanechol (Ureholine), donepezil (Aricept),
  • 6\. Taking steroid medications
  • 7\. Taking vitamins or herbal supplements regularly
  • 8\. Left\-handed participants will be ineligible to take part in Stage Two

Outcomes

Primary Outcomes

Not specified

Similar Trials